Shares of Biocept Inc (NASDAQ:BIOC) have been volatile since the company made its debut as a public company in early February. In an exclusive interview with Benzinga, CEO Michael Nall and CFO Bill Kachioff laid out the company’s opportunities and events investors should watch for in the near future. Biocept is a cancer diagnostics company trying to disrupt the industry by offering a simple blood test versus the standard invasive biopsy. Biocept Inc (NASDAQ:BIOC) stock performance was 7.90% in last session and finished the day at $6.42. Traded volume was 17,863.00million shares in the last session and the average volume of the stock remained 29.65K shares. Biocept Inc (NASDAQ:BIOC) insider ownership is 0.40%.

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 13/977,797, entitled “Compositions and Methods for Treatment of Ovarian Cancer.” The patent relates to inhibition of miR-210 for the treatment of ovarian cancer. Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) rose 6.17 percent to $3.96 Thursday on volume of 219,903.00million shares. The intra-day range of the stock was $3.73 to $4.05. Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) has a market capitalization of $41.46million.

CryoLife, Inc. (NYSE:CRY), a medical device and tissue processing company focused on cardiac and vascular surgery, has appointed James Patrick (Pat) Mackin as President and Chief Executive, effective September 2, 2014. Mackin is expected to be appointed to the Board of Directors soon after his employment. Cryolife Inc (NYSE:CRY)’s stock on July 10, 2014 reported a increase of 5.63% to the closing price of $9.19. Its fifty two weeks range is $6.01 -$12.14. The total market capitalization recorded $257.98million. The overall volume in the last trading session was 226,994.00million shares. In its share capital, CRY has 28.09million outstanding shares.

MabVax Therapeutics, Inc., a privately held cancer immunotherapy company, and Telik, Inc. (NASDAQ:TELK), a publicly-traded clinical stage oncology drug development company, have finalized their merger initially announced on May 12th.  Effective July 8, 2014, MabVax merged with a wholly-owned subsidiary of Telik in an all-stock transaction and became a wholly-owned subsidiary of Telik. On Thursday, shares of Telik, Inc. (NASDAQ:TELK) advanced 9.77% to close the day at $1.46. Company monthly performance is recorded as 3.55%. Telik, Inc. (NASDAQ:TELK) quarterly revenue growth is 5.04%.